Literature DB >> 21214721

Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapy.

Peter P Toth1.   

Abstract

The efficacy of angiotensin receptor blockers (ARBs) in the management of hypertension is well established. Whether these agents induce pleiotropic effects that promote the amelioration of vascular disorders independent of blood pressure reduction remains controversial. This review examines preclinical and clinical data that highlight a potentially important role for ARBs in several common vascular disorders, including cardiovascular, cerebrovascular, renal, and metabolic disorders. The preponderance of evidence suggests that some of the benefits derived from ARBs might improve outcomes in these disorders by actions that extend beyond blood pressure reduction. This review also identifies some potentially important differences in the mechanism of action between ARBs and angiotensin-converting enzyme inhibitors that may have clinical significance in the management of vascular diseases.
© 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21214721      PMCID: PMC8673273          DOI: 10.1111/j.1751-7176.2010.00379.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  59 in total

1.  Chronic angiotensin II AT1 receptor blockade increases cerebral cortical microvessel density.

Authors:  Diane H Munzenmaier; Andrew S Greene
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-09-30       Impact factor: 4.733

2.  Effect of valsartan on the incidence of diabetes and cardiovascular events.

Authors:  John J McMurray; Rury R Holman; Steven M Haffner; M Angelyn Bethel; Björn Holzhauer; Tsushung A Hua; Yuri Belenkov; Mitradev Boolell; John B Buse; Brendan M Buckley; Antonio R Chacra; Fu-Tien Chiang; Bernard Charbonnel; Chun-Chung Chow; Melanie J Davies; Prakash Deedwania; Peter Diem; Daniel Einhorn; Vivian Fonseca; Gregory R Fulcher; Zbigniew Gaciong; Sonia Gaztambide; Thomas Giles; Edward Horton; Hasan Ilkova; Trond Jenssen; Steven E Kahn; Henry Krum; Markku Laakso; Lawrence A Leiter; Naomi S Levitt; Viacheslav Mareev; Felipe Martinez; Chantal Masson; Theodore Mazzone; Eduardo Meaney; Richard Nesto; Changyu Pan; Rudolf Prager; Sotirios A Raptis; Guy E H M Rutten; Herbert Sandstroem; Frank Schaper; Andre Scheen; Ole Schmitz; Isaac Sinay; Vladimir Soska; Steen Stender; Gyula Tamás; Gianni Tognoni; Jaako Tuomilehto; Alberto S Villamil; Juraj Vozár; Robert M Califf
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

3.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

4.  Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis.

Authors:  Nadine Nagy; Ariane Melchior-Becker; Jens W Fischer
Journal:  Basic Res Cardiol       Date:  2009-08-23       Impact factor: 17.165

5.  Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice.

Authors:  Erwin Blessing; Michael Preusch; Roger Kranzhöfer; Ralf Kinscherf; Nikolaus Marx; Michael E Rosenfeld; Berend Isermann; Christian M Weber; Jörg Kreuzer; Julia Gräfe; Hugo A Katus; Florian Bea
Journal:  Atherosclerosis       Date:  2008-02-21       Impact factor: 5.162

6.  Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue.

Authors:  Mi H Lee; Hye K Song; Gang J Ko; Young S Kang; Sang Y Han; Kum H Han; Hyoung K Kim; Jee Y Han; Dae R Cha
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

7.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

Review 8.  Renin-angiotensin system and cardiovascular risk.

Authors:  Roland E Schmieder; Karl F Hilgers; Markus P Schlaich; Bernhard M W Schmidt
Journal:  Lancet       Date:  2007-04-07       Impact factor: 79.321

Review 9.  Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension.

Authors:  Freddy Contreras; María Antonia de la Parte; Julio Cabrera; Nestor Ospino; Zafar H Israili; Manuel Velasco
Journal:  Am J Ther       Date:  2003 Nov-Dec       Impact factor: 2.688

10.  Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells.

Authors:  Martin Steinmetz; Caroline Brouwers; Georg Nickenig; Sven Wassmann
Journal:  J Cell Mol Med       Date:  2009-06-23       Impact factor: 5.310

View more
  3 in total

1.  Renal sympathetic denervation in resistant hypertension.

Authors:  Mário Santos; Henrique Carvalho
Journal:  World J Cardiol       Date:  2013-04-26

Review 2.  Angiotensin receptor blockers: pharmacology, efficacy, and safety.

Authors:  Addison A Taylor; Helmy Siragy; Shawna Nesbitt
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-27       Impact factor: 3.738

3.  Roles of Nitric Oxide and Prostaglandins in the Sustained Antihypertensive Effects of Acanthospermum hispidum DC. on Ovariectomized Rats with Renovascular Hypertension.

Authors:  Rhanany Alan Calloi Palozi; Maysa Isernhagen Schaedler; Cleide Adriane Signor Tirloni; Aniely Oliveira Silva; Francislaine Aparecida Dos Reis Lívero; Roosevelt Isaias Carvalho Souza; Ariany Carvalho Dos Santos; Thiago Bruno Lima Prando; Lauro Mera de Souza; Arquimedes Gasparotto Junior
Journal:  Evid Based Complement Alternat Med       Date:  2017-09-20       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.